Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 6;31(4):202.
doi: 10.1007/s00520-023-07662-1.

MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events

Josephine To  1 , Mellar Davis  2 , Andrea Sbrana  3 , Bryony Alderman  4 , David Hui  5 , Sandip Mukhopadhyay  6 , Carole Bouleuc  7 , Amy A Case  8   9 , Koji Amano  10 , Gregory B Crawford  11 , Giulia de Feo  12 , Kimberson Tanco  5 , Jessica Garsed  13
Affiliations

MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events

Josephine To et al. Support Care Cancer. .

Erratum in

Abstract

Background: Approximately 18% of patients with cancer use cannabis at one time as palliation or treatment for their cancer. We performed a systematic review of randomized cannabis cancer trials to establish a guideline for its use in pain and to summarize the risk of harm and adverse events when used for any indication in cancer patients.

Methods: A systematic review of randomized trials with or without meta-analysis was carried out from MEDLINE, CCTR, Embase, and PsychINFO. The search involved randomized trials of cannabis in cancer patients. The search ended on November 12, 2021. The Jadad grading system was used for grading quality. Inclusion criteria for articles were randomized trials or systematic reviews of randomized trials of cannabinoids versus either placebo or active comparator explicitly in adult patients with cancer.

Results: Thirty-four systematic reviews and randomized trials met the eligibility criteria for cancer pain. Seven were randomized trials involving patients with cancer pain. Two trials had positive primary endpoints, which could not be reproduced in similarly designed trials. High-quality systematic reviews with meta-analyses found little evidence that cannabinoids are an effective adjuvant or analgesic to cancer pain. Seven systematic reviews and randomized trials related to harms and adverse events were included. There was inconsistent evidence about the types and levels of harm patients may experience when using cannabinoids.

Conclusion: The MASCC panel recommends against the use of cannabinoids as an adjuvant analgesic for cancer pain and suggests that the potential risk of harm and adverse events be carefully considered for all cancer patients, particularly with treatment with a checkpoint inhibitor.

Keywords: Adverse events; Cancer; Cannabinoids.

PubMed Disclaimer

References

    1. Anderson SP et al (2019) Impact of medical cannabis on patient-reported symptoms for patients with cancer enrolled in Minnesota’s medical cannabis program. J Oncol Pract 15(4):e338–e345 - PubMed - DOI
    1. Donovan KA et al (2019) Relationship of cannabis use to patient-reported symptoms in cancer patients seeking supportive/palliative care. J Palliat Med 22(10):1191–1195 - PubMed - DOI
    1. Guzmán M (2018) Cannabis for managing cancer symptoms: T.H.C. version 2.0? Cannabis Cannabinoid Res 3(1):117–119 - PubMed - PMC - DOI
    1. Luckett T et al (2016) Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes, and beliefs among patients willing to consider participation. Intern Med J 46(11):1269–1275 - PubMed - DOI
    1. Bar-Lev Schleider L, Abuhasira R, Novack V (2018) Medical cannabis: aligning use to evidence-based medicine approach. Br J Clin Pharmacol 84(11):2458–2462 - PubMed - PMC - DOI

Publication types

LinkOut - more resources